43 results about "Amycolatopsis" patented technology

Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The present invention relates to the new amine salts of HMG-CoA reductase inhibitors, the preparation thereof, the preparation of pure HMG-CoA reductase inhibitors via amine salts thereof, use of the amine salts of HMG-CoA reductase inhibitors in the process for semisynthetic preparation of HMG-CoA reductase inhibitors, use of the amine salts of HMG-CoA reductase inhibitors in the process for biotechnological modification of HMG-CoA reductase inhibitors as well as the conversion of the amine salts of HMG-CoA reductase inhibitors into the pharmaceutically acceptable salts of the HMG-CoA reductase inhibitors and the conversion of the amine salts of HMG-CoA reductase inhibitors into the HMG-CoA reductase inhibitors in the lactone form.

Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, Streptomyces, Actinomadura, Micromonospora, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of HMG-CoA reductase inhibitors using so-called displacement chromatography. Use of the invention enables one to obtain HMG-CoA reductase inhibitors of high purity, with high yields, lower production costs and suitable ecological balance.

The invention discloses a method for preparing A82846B by fermentation. The method is to extract the fermentation culture liquid obtained by fermenting and cultivating Amycolatopsis orientalis, and then carry out alkali degradation on the extracted impurity waste liquid to obtain the alkali degradation liquid. After the alkali degradation solution was added to the fermentation medium, the fermentation was carried out again. By adding different concentrations of impurity alkali degradation solution, the fermentation unit of A82846B was greatly increased, and the components were also significantly improved.

High-efficiency homologous recombination engineering strain of Amycolatopsis, its construction method and application. The invention provides the application of ku1 and / or ku2 gene deletion in improving the efficiency of homologous recombination of Amycolatopsis sp. The engineering strain of Amycobacter lacks the ku1 gene and / or the ku2 gene of Amycolatopsis, and the invention also provides a construction method and application of the strain. In the present invention, it is verified through experiments that the deletion of the ku1 gene, the ku2 gene or the simultaneous deletion of the ku1 gene and the ku2 gene can significantly improve the homologous recombination efficiency of Amycolatopsis. Among them, the homologous recombination efficiency of the engineered strain with deletion of ku1 gene reaches 95%, which has the most prominent effect.

The invention relates to a method for preparing echinosporin antibiotics by fermentation of amycobacteria, which is characterized in that a strain of amycobacteria with a registration number of CCTCC NO: M 2017189 is cultured and preserved by fermentation ( Amycolatopsis speibonae ) YIM PH20520, and then the fermentation product was extracted, concentrated, separated and purified to obtain a molecular weight of 223 and a molecular formula of C 10 h 9 NO 5 echinosporin and its molecular weight is 207, its molecular formula is C 10 h 9 NO 4 7-deoxyechinosporin, the present invention provides a new method and a new approach for the production and preparation of echinosporin antibiotics.